<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208207</url>
  </required_header>
  <id_info>
    <org_study_id>0663-108</org_study_id>
    <nct_id>NCT01208207</nct_id>
  </id_info>
  <brief_title>A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)</brief_title>
  <official_title>A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and tolerability of two doses of
      etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS). The primary
      objectives are to evaluate the improvement in Spinal Pain Intensity over 6 weeks of treatment
      with etoricoxib 90 mg or 60 mg compared to naproxen; and to evaluate the improvement in
      Spinal Pain Intensity over 6 weeks of treatment with etoricoxib 90 mg compared with
      etoricoxib 60 mg. Additionally the added benefit of increasing the dose of etoricoxib from 60
      mg to 90 mg will be assessed in the second part of the study. The primary hypothesis is that
      the improvement in Spinal Pain Intensity visual analog scale (VAS) as measured by the
      time-weighted average (TWA) change from baseline over 6 weeks of treatment in Part I for
      etoricoxib 90 mg or 60 mg once daily is not inferior to naproxen 1000 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen</measure>
    <time_frame>Baseline and up to Week 6</time_frame>
    <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 60 mg vs. Naproxen</measure>
    <time_frame>Baseline and up to Week 6</time_frame>
    <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Treatment Due to an Adverse Event</measure>
    <time_frame>Up to 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Etoricoxib 60 mg</measure>
    <time_frame>Baseline and up to Week 6</time_frame>
    <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Change From Week 6 in the Spinal Pain Intensity Over Weeks 10 and 12 in Study Part 2: Etoricoxib 60/90 mg vs. Etoricoxib 60mg (Non-responders From Part I)</measure>
    <time_frame>Week 6 to Week 10 and Week 12</time_frame>
    <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. Average change from Week 6 in Spinal Pain Intensity (VAS) over Weeks 10 and 12 is calculated as the average Spinal pain Intensity (VAS) value over Weeks 10 and 12 minus the Spinal Pain Intensity (VAS) at Week 6.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1015</enrollment>
  <condition>Spondylitis, Ankylosing</condition>
  <arm_group>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg in Part I and Part II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg in Part I and etoricoxib 90 mg in Part II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etoricoxib 90 mg/etoricoxib 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The etoricoxib 90 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg in Part I and Part II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>naproxen 1000 mg/naproxen 1000 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The naproxen 1000 mg/naproxen 1000 mg treatment sequence will receive naproxen 1000 mg in Part I and Part II</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part I - etoricoxib 60 mg</intervention_name>
    <description>etoricoxib 60 mg oral tablet once daily for 6 weeks</description>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 60 mg</arm_group_label>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 90 mg</arm_group_label>
    <other_name>MK-0663</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part I - etoricoxib 90 mg</intervention_name>
    <description>etoricoxib 90 mg oral tablet once daily for 6 weeks</description>
    <arm_group_label>etoricoxib 90 mg/etoricoxib 90 mg</arm_group_label>
    <other_name>Mk-0663</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part I- naproxen 1000 mg</intervention_name>
    <description>naproxen 500 mg oral tablet twice daily for 6 weeks</description>
    <arm_group_label>naproxen 1000 mg/naproxen 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part I - Placebo to naproxen 500 mg</intervention_name>
    <description>Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks</description>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 60 mg</arm_group_label>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 90 mg</arm_group_label>
    <arm_group_label>etoricoxib 90 mg/etoricoxib 90 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part II- etoricoxib 60 mg</intervention_name>
    <description>etoricoxib 60 mg oral tablet once daily for 20 weeks</description>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 60 mg</arm_group_label>
    <other_name>MK-0663</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part II- etoricoxib 90 mg</intervention_name>
    <description>etoricoxib 90 mg oral tablet once daily for 20 weeks</description>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 90 mg</arm_group_label>
    <arm_group_label>etoricoxib 90 mg/etoricoxib 90 mg</arm_group_label>
    <other_name>MK-0663</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part II- naproxen 1000 mg</intervention_name>
    <description>naproxen 500 mg oral tablet twice daily for 20 weeks</description>
    <arm_group_label>naproxen 1000 mg/naproxen 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part I - Placebo to etoricoxib 60 mg</intervention_name>
    <description>Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.</description>
    <arm_group_label>etoricoxib 90 mg/etoricoxib 90 mg</arm_group_label>
    <arm_group_label>naproxen 1000 mg/naproxen 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part I - Placebo to etoricoxib 90 mg</intervention_name>
    <description>Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.</description>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 60 mg</arm_group_label>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 90 mg</arm_group_label>
    <arm_group_label>naproxen 1000 mg/naproxen 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part II- Placebo to etoricoxib 60 mg</intervention_name>
    <description>Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.</description>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 90 mg</arm_group_label>
    <arm_group_label>etoricoxib 90 mg/etoricoxib 90 mg</arm_group_label>
    <arm_group_label>naproxen 1000 mg/naproxen 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part II - Placebo to etoricoxib 90 mg</intervention_name>
    <description>Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.</description>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 60 mg</arm_group_label>
    <arm_group_label>naproxen 1000 mg/naproxen 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part II- Placebo to naproxen 500 mg</intervention_name>
    <description>Placebo to naproxen 500 mg orally twice daily for 20 weeks.</description>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 60 mg</arm_group_label>
    <arm_group_label>etoricoxib 60 mg/etoricoxib 90 mg</arm_group_label>
    <arm_group_label>etoricoxib 90 mg/etoricoxib 90 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a definite diagnosis of Ankylosing Spondylitis (AS) per Modified New York Criteria
             made at least 6 months prior to screening

          -  Has a history of positive therapeutic benefit with non-steroidal anti-inflammatory
             drugs (NSAIDs) and regular use of NSAIDS for past 30 days

          -  Has a score on Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2
             at screening visit that is &lt;77 mm

          -  Must demonstrate sufficient &quot;flare&quot; or worsening of AS pain

          -  Is in general good health (other than AS)

          -  Has had approved non-study antirheumatic therapy that has been at stable dosing AND is
             not anticipated to undergo a change within the first 6 weeks of the protocol

        Exclusion Criteria:

          -  Has inflammatory arthritis (eg, rheumatoid arthritis, psoriatic arthritis,
             crystal-induced arthritis, spondyloarthropathy, diffuse idiopathic skeletal
             hyperostosis [DISH]), polymyalgia rheumatica, a history of septic arthritis or
             intra-articular fracture of the study joint, Wilson's disease, hemachromatosis,
             ochronosis, or primary osteochondromatosis

          -  Has acute peripheral articular disease (onset within 4 weeks prior to screening) of an
             active (painful or swollen) peripheral arthritis

          -  Has a history of gastric or biliary surgery, or small intestine surgery that causes
             clinical malabsorption

          -  Has had an active peptic (gastric or duodenal) ulcer or history of inflammatory bowel
             disease

          -  Has undergone coronary artery bypass graft surgery (CABG), angioplasty, or has a
             cerebrovascular accident or transient ischemic attack within the past 6 months or has
             active ischemic heart disease, cerebrovascular disease, or peripheral vascular disease

          -  Has Class II-IV congestive heart failure

          -  Has uncontrolled hypertension

          -  Has a history of neoplastic disease, except adequately treated basal cell carcinoma or
             carcinoma in situ of the cervix, or malignancies that have been successfully treated ≥
             5 years prior to screening

          -  Has history of leukemia, lymphoma, malignant melanoma, and myeloproliferative disease

          -  Allergy to etoricoxib or naproxen, or history of a significant clinical or laboratory
             adverse experience associated with etoricoxib or naproxen

          -  Has a history or family history of an inherited or acquired bleeding disorder

          -  Is considered morbidly obese and demonstrates significant health problems stemming
             from obesity, which would confound study participation or interpretation of study
             results

          -  Is pregnant, breast-feeding, or expecting to conceive during the study

          -  Has a clinical diagnosis of hepatic insufficiency defined as Child-Pugh score ≥ 5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Balazcs E, Sieper J, Bickham K, Mehta A, Frontera N, Stryszak P, Popmihajlov Z, Peloso PM. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2016 Oct 13;17(1):426.</citation>
    <PMID>27737664</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2010</study_first_submitted>
  <study_first_submitted_qc>September 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <results_first_submitted>May 4, 2015</results_first_submitted>
  <results_first_submitted_qc>June 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2015</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=0663-108&amp;kw=0663-108&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All Patients Randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etoricoxib 60 mg (Part I)</title>
          <description>Etoricoxib 60 mg oral tablet once daily for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Etoricoxib 90 mg (Part I)</title>
          <description>Etoricoxib 90 mg oral tablet once daily for 6 weeks</description>
        </group>
        <group group_id="P3">
          <title>Naproxen 1000 mg (Part I)</title>
          <description>Naproxen 500 mg oral tablet twice daily for 6 weeks</description>
        </group>
        <group group_id="P4">
          <title>Etoricoxib 60 mg / 60 mg (Part II)</title>
          <description>A continuation of the etoricoxib 60 mg oral tablet once daily for 20 weeks (Part II)</description>
        </group>
        <group group_id="P5">
          <title>Etoricoxib 60 mg / 90 mg (Part II)</title>
          <description>An increase of etoricoxib to 90 mg for 20 weeks (Part II)</description>
        </group>
        <group group_id="P6">
          <title>Etoricoxib 90 mg / 90 mg (Part II)</title>
          <description>A continuation of the etoricoxib 90 mg oral tablet once daily for 20 weeks (Part II)</description>
        </group>
        <group group_id="P7">
          <title>Naproxen 1000 mg (Part II)</title>
          <description>A continuation of the naproxen 500 mg oral tablet twice daily for 20 weeks (Part II)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="702"/>
                <participants group_id="P2" count="156"/>
                <participants group_id="P3" count="157"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="632"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="142"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="314"/>
                <participants group_id="P5" count="318"/>
                <participants group_id="P6" count="145"/>
                <participants group_id="P7" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="282"/>
                <participants group_id="P5" count="295"/>
                <participants group_id="P6" count="129"/>
                <participants group_id="P7" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="16"/>
                <participants group_id="P7" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance With Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical Problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etoricoxib 60 mg</title>
          <description>Etoricoxib 60 mg oral tablet once daily</description>
        </group>
        <group group_id="B2">
          <title>Etoricoxib 90 mg</title>
          <description>Etoricoxib 90 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Naproxen 1000 mg</title>
          <description>Naproxen 500 mg oral tablet twice daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="702"/>
            <count group_id="B2" value="156"/>
            <count group_id="B3" value="157"/>
            <count group_id="B4" value="1015"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="12.4"/>
                    <measurement group_id="B2" value="45.2" spread="11.3"/>
                    <measurement group_id="B3" value="44.5" spread="12.3"/>
                    <measurement group_id="B4" value="45.2" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="295"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="493"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spinal Pain Intensity</title>
          <description>Visual Analogue Scale from 0-100 mm with a lower value representing a better response.</description>
          <units>mm VAS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.7" spread="14.2"/>
                    <measurement group_id="B2" value="76.7" spread="15.2"/>
                    <measurement group_id="B3" value="77.0" spread="14.0"/>
                    <measurement group_id="B4" value="76.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen</title>
        <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.</description>
        <time_frame>Baseline and up to Week 6</time_frame>
        <population>Per-Protocol Population - excluded participants due to important protocol deviations that may have had a substantial effect on the result of the primary efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 90 mg</title>
            <description>Etoricoxib 90 mg oral tablet once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Naproxen 1000 mg</title>
            <description>Naproxen 500 mg oral tablet twice daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen</title>
          <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.</description>
          <population>Per-Protocol Population - excluded participants due to important protocol deviations that may have had a substantial effect on the result of the primary efficacy endpoint.</population>
          <units>mm VAS</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.23" lower_limit="-34.70" upper_limit="-27.76"/>
                    <measurement group_id="O2" value="-30.59" lower_limit="-34.07" upper_limit="-27.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The etoricoxib dose (90 mg) will be considered non-inferior to naproxen 1000 mg if the upper bound of the two-sided 95% confidence interval of the between-treatment difference in the least squares (LS) mean (etoricoxib minus naproxen 1000 mg) is no larger than 8 mm VAS (non-inferiority margin).</non_inferiority_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.47</ci_lower_limit>
            <ci_upper_limit>4.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 60 mg vs. Naproxen</title>
        <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.</description>
        <time_frame>Baseline and up to Week 6</time_frame>
        <population>Per-Protocol Population - excluded participants due to important protocol deviations that may have had a substantial effect on the result of the primary efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 60 mg</title>
            <description>Etoricoxib 60 mg oral tablet once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Naproxen 1000 mg</title>
            <description>Naproxen 500 mg oral tablet twice daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 60 mg vs. Naproxen</title>
          <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.</description>
          <population>Per-Protocol Population - excluded participants due to important protocol deviations that may have had a substantial effect on the result of the primary efficacy endpoint.</population>
          <units>mm VAS</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="660"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.00" lower_limit="-30.69" upper_limit="-27.31"/>
                    <measurement group_id="O2" value="-30.59" lower_limit="-34.07" upper_limit="-27.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The etoricoxib dose (60 mg) will be considered non-inferior to naproxen 1000 mg if the upper bound of the two-sided 95% confidence interval of the between-treatment difference in the LS mean (etoricoxib minus naproxen 1000 mg) is no larger than 8 mm VAS (non-inferiority margin).</non_inferiority_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.19</ci_lower_limit>
            <ci_upper_limit>5.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Etoricoxib 60 mg</title>
        <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.</description>
        <time_frame>Baseline and up to Week 6</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population - the mITT population in Part I consisted of all randomized participants who received at least 1 dose of study treatment, had at least 1 measurement of interest post-randomization that was collected within 3 days of the last dose of study medication taken in Part I, and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 90 mg</title>
            <description>Etoricoxib 90 mg oral tablet once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 60 mg</title>
            <description>Etoricoxib 60 mg oral tablet once daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Etoricoxib 60 mg</title>
          <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.</description>
          <population>Modified Intent-to-Treat (mITT) Population - the mITT population in Part I consisted of all randomized participants who received at least 1 dose of study treatment, had at least 1 measurement of interest post-randomization that was collected within 3 days of the last dose of study medication taken in Part I, and had baseline data.</population>
          <units>mm VAS</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="694"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.51" lower_limit="-33.87" upper_limit="-27.15"/>
                    <measurement group_id="O2" value="-28.94" lower_limit="-30.58" upper_limit="-27.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.396</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.96</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Change From Week 6 in the Spinal Pain Intensity Over Weeks 10 and 12 in Study Part 2: Etoricoxib 60/90 mg vs. Etoricoxib 60mg (Non-responders From Part I)</title>
        <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. Average change from Week 6 in Spinal Pain Intensity (VAS) over Weeks 10 and 12 is calculated as the average Spinal pain Intensity (VAS) value over Weeks 10 and 12 minus the Spinal Pain Intensity (VAS) at Week 6.</description>
        <time_frame>Week 6 to Week 10 and Week 12</time_frame>
        <population>Modified Intent-to-Treat (mITT) Population - the mITT population in Part I consisted of all randomized participants who received at least 1 dose of study treatment, had at least 1 measurement of interest post-randomization that was collected within 3 days of the last dose of study medication taken in Part I, and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 60 mg/ 90 mg</title>
            <description>Etoricoxib 60 mg in Part I and Etoricoxib 90 mg in Part II</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 60 mg / 60 mg</title>
            <description>Etoricoxib 60 mg in Part I and Etoricoxib 60 mg in Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change From Week 6 in the Spinal Pain Intensity Over Weeks 10 and 12 in Study Part 2: Etoricoxib 60/90 mg vs. Etoricoxib 60mg (Non-responders From Part I)</title>
          <description>Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. Average change from Week 6 in Spinal Pain Intensity (VAS) over Weeks 10 and 12 is calculated as the average Spinal pain Intensity (VAS) value over Weeks 10 and 12 minus the Spinal Pain Intensity (VAS) at Week 6.</description>
          <population>Modified Intent-to-Treat (mITT) Population - the mITT population in Part I consisted of all randomized participants who received at least 1 dose of study treatment, had at least 1 measurement of interest post-randomization that was collected within 3 days of the last dose of study medication taken in Part I, and had baseline data.</population>
          <units>mm VAS</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.97" lower_limit="-12.42" upper_limit="-7.51"/>
                    <measurement group_id="O2" value="-7.26" lower_limit="-9.73" upper_limit="-4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.112</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-2.70</param_value>
            <ci_percent>80</ci_percent>
            <ci_lower_limit>-4.88</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinuing Study Treatment Due to an Adverse Event</title>
        <time_frame>Up to 26 weeks</time_frame>
        <population>All Patients as Treated Population (APaT) - Participants were included in the treatment group corresponding to the study treatment they actually received. One participant randomized to 60 mg in Part II received 90 mg in Part II, and; therefore, was included in the Etoricoxib 60mg / 90mg (Part II) arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 60 mg (Part I)</title>
            <description>Etoricoxib 60 mg oral tablet once daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 90 mg (Part I)</title>
            <description>Etoricoxib 90 mg oral tablet once daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Naproxen 1000 mg (Part I)</title>
            <description>Naproxen 500 mg oral tablet twice daily for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>Etoricoxib 60 mg / 60 mg (Part II)</title>
            <description>A continuation of the etoricoxib 60 mg oral tablet once daily for 20 weeks (Part II)</description>
          </group>
          <group group_id="O5">
            <title>Etoricoxib 60 mg / 90 mg (Part II)</title>
            <description>An increase of etoricoxib to 90 mg for 20 weeks (Part II)</description>
          </group>
          <group group_id="O6">
            <title>Etoricoxib 90 mg / 90 mg (Part II)</title>
            <description>A continuation of the etoricoxib 90 mg oral tablet once daily for 20 weeks (Part II)</description>
          </group>
          <group group_id="O7">
            <title>Naproxen 1000 mg (Part II)</title>
            <description>A continuation of the naproxen 500 mg oral tablet twice daily for 20 weeks (Part II)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Study Treatment Due to an Adverse Event</title>
          <population>All Patients as Treated Population (APaT) - Participants were included in the treatment group corresponding to the study treatment they actually received. One participant randomized to 60 mg in Part II received 90 mg in Part II, and; therefore, was included in the Etoricoxib 60mg / 90mg (Part II) arm.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="702"/>
                <count group_id="O2" value="155"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="313"/>
                <count group_id="O5" value="319"/>
                <count group_id="O6" value="145"/>
                <count group_id="O7" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 30 (including up to 28 days after last dose of study drug)</time_frame>
      <desc>AE's were collected for the All Patients as Treated Population. Participants were included in the treatment group corresponding to the study treatment they actually received. One participant randomized to Etoricoxib 60 mg in Part II received Etoricoxib 90 mg in Part II, and; therefore, was included in the Etoricoxib 60mg / 90mg (Part II) arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Etoricoxib 60 mg / Etoricoxib 60 mg</title>
          <description>Participants who received Etoricoxib 60 mg in Part I and at least one dose of Etoricoxib 60 mg in Part II.</description>
        </group>
        <group group_id="E2">
          <title>Etoricoxib 60 mg / Etoricoxib 90 mg</title>
          <description>Participants who received Etoricoxib 60 mg in Part I and at least one dose of Etoricoxib 90 mg in Part II.</description>
        </group>
        <group group_id="E3">
          <title>Etoricoxib 90 mg / Etoricoxib 90 mg</title>
          <description>Participants who received Etoricoxib 90 mg in Part I and at least one dose of Etoricoxib 90 mg in Part II.</description>
        </group>
        <group group_id="E4">
          <title>Naproxen 1000 mg / Naproxen 1000 mg</title>
          <description>Participants who received Naproxen 1000 mg in Part I and at least one dose of Naproxen 1000 mg in Part II.</description>
        </group>
        <group group_id="E5">
          <title>Etoricoxib 60 mg</title>
          <description>Participants who received at least one dose of Etoricoxib 60 mg in Part I, but no drug in Part II.</description>
        </group>
        <group group_id="E6">
          <title>Etoricoxib 90 mg</title>
          <description>Participants who received at least one dose of Etoricoxib 90 mg in Part I, but no drug in Part II.</description>
        </group>
        <group group_id="E7">
          <title>Naproxen 1000 mg</title>
          <description>Participants who received at least one dose of Naproxen 1000 mg in Part I, but no drug in Part II.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="319"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title vocab="MedDRA Version 17.1">Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ear neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title vocab="MedDRA Version 17.1">Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title vocab="MedDRA Version 17.1">Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title vocab="MedDRA Version 17.1">Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA Version 17.1">Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title vocab="MedDRA Version 17.1">Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="313"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="319"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="145"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="142"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 17.1">Abdominal pain upper</sub_title>
                <counts group_id="E1" events="28" subjects_affected="15" subjects_at_risk="313"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="319"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="142"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="313"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="319"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="313"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 17.1">Nasopharyngitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="313"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="319"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="313"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 17.1">Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="313"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="319"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="145"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E5" events="13" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Anosmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="319"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 17.1">Hypertension</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="313"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="319"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

